Gruppo Peri

Coordinator of Research Team

Name Alessandro Peri

Position Associate Professor

Name of Research Team/Laboratory:  Neuroendocrinology research team  


telephone number 055 2758432



Brief biographical sketch of the Coordinator (date of birth, degrees and Universities where they have been obtained)


Date of birth: March 18, 1964

October 1989 Degree in Medicine

1991-1994 Visiting Fellow, Section on Developmental Genetics, Human Genetics Branch, National Institute of Child  Health and Human Development, The National Institutes of Health, Bethesda, Maryland.

October 1995 PhD in Endocrine Sciences, University of Florence, Italy

November, 1999 Board certified in Endocrinology, University of Florence, Italy

June 1997    Assistant Professor of Endocrinology, University of Florence. Italy

December 2004 Associate Professor of Endocrinology, University of Florence, Italy



Member of the scientific board of the Doctorate/PhD Program in

Biomedical Sciences, University of Florence, Italy


Member of the following Scientific Societies

1) Italian Society of Endocrinology

                2) European Society of Endocrinology



Member of the editorial board of the following Journals

1) Journal of Endocronological Investigation

                2) L’Endocrinologo         


Research Team

                1) Susanna Benvenuti, PhD 1/27/1957

                2) Paola Luciani, PhD 6/29/1970

                3) Benedetta Fibbi, MD, PhD 11/13/1980


Current research interests 

Effects of low sodium concentrations on the nervous system

Effects of low sodium concentrations on bone

Characterization of human neural crest cells as a model for assessing the effects of endocrine disruptors in the nervous system


Current / recent sources of funding

                1) Ente Cassa di Risparmio di Firenze

                2) Otsuka Pharmaceutical

                3) Novartis


10 best publications of the last 5 years


1) Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, Maggi M, Peri A Moderate hyponatremia is associated with  increased risk of mortality: evidence from a meta-analysis. Plos One 8:e80451,

2) Peri A. The use of vaptans in clinical endocrinology. J. Clin. Endocrinol. Metab., 98:1321-1332, 2013

3) Luciani P, Deledda C, Benvenuti S, Squecco R, Cellai I, Marone IM, Giuliani C, Modi G, Francini F, Vannelli GB, Peri A Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. Plos One 8:e71716, 2013

4) Greenberg A, Verbalis JG, Amin A, Burst V, Chiodo III JA, Chiong J, Dasta J, Friend K, Hauptman PJ,  Peri A, Sigal S, Hyponatremia: Current Treatment Practice and Outcomes  Report of the Hyponatremia Registry: an Observational Multicenter International Study.  Kidney Int 10:e0124105, 2015

5) Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis., Plos One, 11:e0152846, 2015

6) Corona G, Giuliani C, Parenti G, Colombo GL, Sforza A, Maggi M, Forti G, Peri A.  The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis. Am J Med. 129:823-835, 2016

7) Verbalis JG, Greenberg A, Burst V, Haymann JP, Johannsson G, Peri A, Poch E, Chiodo JA 3rd, Dave J. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med.  129:537.e9-537.e23, 2016 8) Fibbi B, Benvenuti S, Giuliani C, Deledda C, Luciani P, Monici M, Mazzanti B, Ballerini C, Peri A. Low extracellular sodium promotes adipogenic commitment of human mesenchymal stromal cells: a novel mechanism for chronic hyponatremia-induced bone loss. Endocrine. 2016 Apr;52(1):73-85. 9) Peri A, Grohé C, Berardi R, Runkle I. SIADH: differential diagnosis and clinical management. Endocrine. 55:311-319, 2017 10) Bhandari S, Peri A, Cranston I, McCool R, Shaw A, Glanville J, Petrakova L, O'Reilly K. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clin Endocrinol (Oxf). 2017 Jun;86(6):761-771.  

Previous research experiences

Antineoplastic effects of GLP-1 analogues

Neuroprotective effects of estrogen and estrogen-receptor modulators

Effects of cAMP responsive element binding protein/modulator on pituitary cell proliferation

Gynecological endocrinology (uteroglobin, endothelin)


Main scientific contributions


- Clinical studies and meta-analyses clearly indicated that hyponatremia increases the risk of fall and fractures and also the risk of mortality of hospitalized patients. In addition, hyponatremia is associated with an increased length of hospital stay and therefore with increased costs.

- Basic research studies allowed to demonstrate for the first time that the neurological alterations caused by hyponatremia are, at least partially, due  to non osmotic-related  perturbations. 

- Extensive experimental work showed for the first time that estrogen and estrogen-receptor modulators have a neuroprotective effect through the activation of the anti-apoptotic gene seladin-1. These data are in agreement with the hypothesis that these molecules might prevent o delay the onset and/or course of neurodegenerative diseases, such as Alzheimer’s disease


Current collaborations

Steering Committee member of  the  European Hyponatremia Network . Collaborations with Prof Christian Grohe and Dr Volker Burst (Germany), Prof. Isabelle Runkle De La Vega and Prof. Alberto Tejador (Spain), Prof. Christopher Thompson (Ireland), Prof. Rossana Berardi (Italy

Prof. Joseph Verbalis (Georgetown  University, Washington DC)

Group for the study of pituitary tumors (Italian Endocrine Society)

Group for the study of electrolyte disorders (Coordinator, Italian Endocrine Society)

Ultimo aggiornamento



I cookie di questo sito servono al suo corretto funzionamento e non raccolgono alcuna tua informazione personale. Se navighi su di esso accetti la loro presenza.  Maggiori informazioni